In the 2024 Type 2 Diabetes Canadian Guidelines, metformin still tops the list as 1st line. 

Why? Its efficacy in lowering a1c, no hypoglycemia or weight gain, long-term safety record, and affordability.

GLP1 & SGLT2s should be added for cardiorenal protection in those already with the diagnosis.